A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00144482

Enrollment

122

Registered

2005-09-05

Start date

2003-12-31

Completion date

2005-08-31

Last updated

2009-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Induced Anemia

Brief summary

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Interventions

DRUGrecombinant human erythropoietin

36000IU（0.5mL）s.c./week for 8 weeks

DRUGrecombinant human erythropoietin placebo

0 IU(0.5mL)s.c./week for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 79 Years

Healthy volunteers

Inclusion criteria

* Cancer patients

Exclusion criteria

* a history of myocardial, cerebral or pulmonary infarction * severe hypertension beyond control by drugs

Design outcomes

Primary

Measure	Time frame
The increase in Hb concentration	week 8

Secondary

Measure	Time frame
Changes in QOL scores	8 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026